Literature DB >> 33595913

Association between sex hormones regulation-related SNP rs12233719 and lung cancer risk among never-smoking Chinese women.

Ying Qian1, Li Xie1,2, Lei Li1, Tienan Feng2, Tengteng Zhu2, Ruoyang Wang1, Yuqing Yang1, Baosen Zhou3, Herbert Yu4, Biyun Qian1,5.   

Abstract

BACKGROUND: The mechanism of rapidly increased non-small cell lung cancer (NSCLC) among never-smoking Chinese women has not been elucidated. Ovarian sex steroid hormones have been suggested to counteract lung cancer development, and sex hormone-binding globulin (SHBG) is essential in sex hormones regulation. This study aims to exploring single nucleotide polymorphisms (SNPs) in genomic regions associated with SHBG concentrations that contributed to never-smoking female NSCLC.
METHODS: Candidate genes were selected by a genome-wide association (GWAS) meta-analysis and gene expression profiles of never-smoking NSCLC of Chinese women. The candidate SNPs limited to common minor allele frequency (MAF), missense variant, ethnic heterogeneous distribution, and SNPs were genotyped using the TaqMan method. A two-stage case-control design was adopted for exploration and validation of associations between candidate SNPs and risk of NSCLC. All participants were never-smoking Chinese women. Chi-square test and multivariate logistic regression were applied.
RESULTS: Beginning with 12 genomic regions associated with circulating SHBG concentrations and gene expression profiles from never-smoking NSCLC in Chinese women, candidate SNP rs12233719 and rs7439366 both located in candidate gene UGT2 B7, which may be related to circulating SHBG concentrations and cancer risk, were identified. A two-stage case-control study was conducted in Shenyang and Tianjin represented as the training stage and validation stage, respectively. Under the dominant model, compared to individuals with the wild G/G genotype, the adjusted OR of those with the T allele was 1.58 (95% CI: 1.15-2.16) in Chinese Shenyang training set, and was 1.49 (95% CI: 1.02-2.18) in Chinese Tianjin validation set, both accompanied with a significant trend relationship consistently. UGT2B7 was upregulated in female NSCLC patients' tumor tissues and was associated with a poor prognosis in NSCLC.
CONCLUSION: Our findings indicated that a sex hormones regulation-related SNP rs12233719 was associated with never-smoking female lung cancer risk, which might partially explain NSCLC-susceptibility in Chinese women.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Chinese women; SNP; lung cancer; never-smoking; sex hormones regulation

Mesh:

Substances:

Year:  2021        PMID: 33595913      PMCID: PMC7940208          DOI: 10.1002/cam4.3772

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  28 in total

1.  Two-stage case-control studies: precision of parameter estimates and considerations in selecting sample size.

Authors:  James A Hanley; Ilona Csizmadi; Jean-Paul Collet
Journal:  Am J Epidemiol       Date:  2005-11-03       Impact factor: 4.897

Review 2.  Computational methods for transcriptome annotation and quantification using RNA-seq.

Authors:  Manuel Garber; Manfred G Grabherr; Mitchell Guttman; Cole Trapnell
Journal:  Nat Methods       Date:  2011-05-27       Impact factor: 28.547

Review 3.  Sex hormone binding globulin: origin, function and clinical significance.

Authors:  C Selby
Journal:  Ann Clin Biochem       Date:  1990-11       Impact factor: 2.057

Review 4.  Associations between UGT2B7 polymorphisms and cancer susceptibility: A meta-analysis.

Authors:  Ming-Li Shen; An Xiao; Sun-Jun Yin; Ping Wang; Xiao-Qian Lin; Chen-Bin Yu; Gong-Hao He
Journal:  Gene       Date:  2019-05-10       Impact factor: 3.688

5.  Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium.

Authors:  Johanie Lépine; Olivier Bernard; Marie Plante; Bernard Têtu; Georges Pelletier; Fernand Labrie; Alain Bélanger; Chantal Guillemette
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

6.  Genetic polymorphism in UDP-glucuronosyltransferase 2B7 and colorectal cancer risk.

Authors:  E M J van der Logt; R H M te Morsche; N Groenendaal; H M J Roelofs; M de Metz; J W van der Stappen; F M Nagengast; W H M Peters
Journal:  Oncol Res       Date:  2009       Impact factor: 5.574

7.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

8.  Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women.

Authors:  Deborah J Thompson; Catherine S Healey; Caroline Baynes; Bolot Kalmyrzaev; Shahana Ahmed; Mitch Dowsett; Elizabeth Folkerd; Robert N Luben; David Cox; Dennis Ballinger; Paul D P Pharoah; Bruce A J Ponder; Alison M Dunning; Douglas F Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

9.  Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.

Authors:  Li-Han Hsu; Ko-Jiunn Liu; Ming-Fang Tsai; Chang-Ru Wu; An-Chen Feng; Nei-Min Chu; Shu-Huei Kao
Journal:  Cancer Sci       Date:  2014-11-28       Impact factor: 6.716

10.  Genetic Polymorphisms in the Vitamin D Pathway and Non-small Cell Lung Cancer Survival.

Authors:  Jinyu Kong; Xiaojie Chen; Jian Wang; Jingxin Li; Fangxiu Xu; Shegan Gao; Herbert Yu; Biyun Qian
Journal:  Pathol Oncol Res       Date:  2019-10-17       Impact factor: 3.201

View more
  1 in total

1.  The association between different hormone replacement therapy use and the incidence of lung cancer: a systematic review and meta-analysis.

Authors:  Hui Wen; Xuefeng Lin; Daqiang Sun
Journal:  J Thorac Dis       Date:  2022-02       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.